131 related articles for article (PubMed ID: 38772998)
1. Lutetium [
Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38772998
[TBL] [Abstract][Full Text] [Related]
2. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
3. [
Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted indirect treatment comparison of [
Khan MS; Stamp E; Sammon C; Brabander T; de Herder WW; Pavel ME
EJC Suppl; 2021 Nov; 16():5-13. PubMed ID: 34912478
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
6. Use of [
Glover M; Caplin M; Leeuwenkamp OR; Longworth L
EJC Suppl; 2021 Nov; 16():14-23. PubMed ID: 34912479
[TBL] [Abstract][Full Text] [Related]
7. Radioligand Therapy with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Mróz A; Żmudzki W; Kamiński G
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765013
[TBL] [Abstract][Full Text] [Related]
8. [
Singh S; Halperin D; Myrehaug S; Herrmann K; Pavel M; Kunz PL; Chasen B; Tafuto S; Lastoria S; Capdevila J; García-Burillo A; Oh DY; Yoo C; Halfdanarson TR; Falk S; Folitar I; Zhang Y; Aimone P; de Herder WW; Ferone D;
Lancet; 2024 Jun; ():. PubMed ID: 38851203
[TBL] [Abstract][Full Text] [Related]
9. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
10. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of [
Hertelendi M; Belguenani O; Cherfi A; Folitar I; Kollar G; Polack BD
Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189646
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center.
Silva MM; Canha M; Salazar D; Neves JS; Ferreira G; Carvalho D; Duarte H
Cureus; 2023 Oct; 15(10):e47506. PubMed ID: 38021538
[TBL] [Abstract][Full Text] [Related]
14. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
[TBL] [Abstract][Full Text] [Related]
15. Prediction of [
Ha S; Kim YI; Oh JS; Yoo C; Ryoo BY; Ryu JS
EJNMMI Phys; 2024 Feb; 11(1):14. PubMed ID: 38315270
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Kapusta W; Żmudzki W; Mróz A; Kos-Kudła B; Kamiński G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001726
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
[No Abstract] [Full Text] [Related]
18. Relationships between uptake of [
Stenvall A; Gustafsson J; Larsson E; Roth D; Sundlöv A; Jönsson L; Hindorf C; Ohlsson T; Sjögreen Gleisner K
EJNMMI Res; 2022 Dec; 12(1):75. PubMed ID: 36534192
[TBL] [Abstract][Full Text] [Related]
19. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
[TBL] [Abstract][Full Text] [Related]
20. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
